Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook
TipRanksApr 26 00:35
Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
Zhitong FinanceApr 24 01:20
Prime Medicine Analyst Ratings
BenzingaApr 24 01:13
Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target
BenzingaApr 24 01:14
Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress
TipRanksApr 22 19:55
Prime Medicine (PRME.US) was first covered by Chardan Capital, giving it a buy rating, with a target price of $17.00.
Zhitong FinanceApr 22 19:50
Prime Medicine Analyst Ratings
BenzingaApr 22 19:48
Chardan Capital Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $17
BenzingaApr 22 19:49
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanksApr 12 19:10
Prime Medicine (PRME.US) was first covered by TD Cowen, giving it a buy rating.
Zhitong FinanceApr 9 05:20
Prime Medicine Analyst Ratings
BenzingaApr 9 05:18
Prime Medicine Analyst Ratings
BenzingaApr 3 04:24
Wedbush Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $12
BenzingaApr 3 04:24
Analysts' Top Healthcare Picks: Prime Medicine, Inc. (PRME), Alcidion Group Limited (AU:ALC)
TipRanksMar 20 17:07
Buy Rating Justified: Prime Medicine's Promising Clinical Prospects and Innovative Gene Editing Technology Poised for Growth
TipRanksMar 12 19:06
Prime Medicine Analyst Ratings
BenzingaMar 6 01:03
Guggenheim Maintains Buy on Prime Medicine, Lowers Price Target to $20
BenzingaMar 6 01:04
Buy Rating Affirmed for Prime Medicine, Inc. on Anticipated IND Filing and Strong Gene Editing Pipeline
TipRanksMar 4 20:26
Stifel Cuts Prime Medicine to Hold, Cites Quieter Catalyst Outlook
Seeking AlphaJan 17 04:41
Citigroup Initiates Coverage On Prime Medicine With Neutral Rating, Announces Price Target of $10
BenzingaDec 8, 2023 20:38
No Data
No Data